Total Payments
$412,665
2024 Payments
$8,105
Companies
15
Transactions
675
Medicare Patients
1,754
Medicare Billing
$147,006
Payment Breakdown by Category
Other$351,142 (85.1%)
Consulting$30,428 (7.4%)
Food & Beverage$16,060 (3.9%)
Travel$15,010 (3.6%)
Education$26.28 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $351,142 | 233 | 85.1% |
| Consulting Fee | $30,428 | 13 | 7.4% |
| Food and Beverage | $16,060 | 339 | 3.9% |
| Travel and Lodging | $15,010 | 86 | 3.6% |
| Education | $26.28 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $151,045 | 151 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $77,621 | 80 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $63,851 | 125 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $56,884 | 100 | $0 (2020) |
| Lilly USA, LLC | $37,743 | 148 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23,886 | 57 | $0 (2021) |
| Mannkind Corporation | $650.00 | 1 | $0 (2020) |
| IBSA Pharma Inc. | $500.00 | 1 | $0 (2022) |
| Horizon Therapeutics plc | $240.86 | 2 | $0 (2022) |
| Medtronic MiniMed, Inc. | $101.37 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,105 | 22 | Novo Nordisk Inc ($7,755) |
| 2023 | $22,693 | 40 | Novo Nordisk Inc ($18,494) |
| 2022 | $42,800 | 52 | Novo Nordisk Inc ($27,738) |
| 2021 | $51,172 | 64 | Novo Nordisk Inc ($22,111) |
| 2020 | $35,010 | 65 | SANOFI-AVENTIS U.S. LLC ($11,057) |
| 2019 | $86,544 | 147 | Novo Nordisk Inc ($21,442) |
| 2018 | $94,471 | 142 | Novo Nordisk Inc ($42,462) |
| 2017 | $71,871 | 143 | Lilly USA, LLC ($26,367) |
All Payment Transactions
675 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Diabetes | ||||||
| 09/27/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 09/12/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Diabetes | ||||||
| 09/10/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 07/10/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Diabetes | ||||||
| 06/27/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 06/24/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Diabetes | ||||||
| 06/13/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 06/12/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 06/07/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 05/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/07/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Diabetes | ||||||
| 04/23/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 04/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/01/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,754.50 | General |
| Category: Diabetes | ||||||
| 03/28/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 03/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/26/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Diabetes | ||||||
| 02/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Diabetes | ||||||
| 02/06/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/01/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Diabetes | ||||||
| 01/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Diabetes | ||||||
| 12/14/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/01/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 11/29/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 461 | 598 | $140,219 | $39,669 |
| 2022 | 6 | 390 | 515 | $98,304 | $36,652 |
| 2021 | 6 | 472 | 612 | $98,502 | $40,153 |
| 2020 | 8 | 431 | 538 | $89,468 | $30,532 |
Total Patients
1,754
Total Services
2,263
Medicare Billing
$147,006
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 205 | 293 | $85,237 | $20,170 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 60 | 60 | $16,342 | $5,135 | 31.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 35 | $11,459 | $4,503 | 39.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 66 | $7,695 | $4,081 | 53.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 52 | 76 | $4,607 | $2,032 | 44.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 41 | $9,102 | $1,679 | 18.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $2,875 | $1,323 | 46.0% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 14 | 14 | $2,902 | $745.68 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 199 | 289 | $55,811 | $19,536 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 68 | 68 | $17,947 | $6,393 | 35.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 38 | $12,442 | $5,768 | 46.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 41 | $4,780 | $2,299 | 48.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 38 | 50 | $3,486 | $1,388 | 39.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 29 | $3,838 | $1,268 | 33.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 211 | 289 | $49,898 | $20,800 | 41.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 59 | 59 | $15,850 | $6,142 | 38.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 31 | 32 | $10,477 | $5,090 | 48.6% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2021 | 65 | 111 | $9,476 | $3,796 | 40.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 68 | 74 | $9,477 | $3,022 | 31.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 38 | 47 | $3,324 | $1,304 | 39.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 145 | 215 | $37,736 | $12,345 | 32.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 65 | 65 | $17,155 | $6,094 | 35.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 95 | 117 | $13,639 | $4,000 | 29.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $5,239 | $2,597 | 49.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 53 | 59 | $6,878 | $2,109 | 30.7% |
About Dr. Seth Charatz, D.O
Dr. Seth Charatz, D.O is a Hospitalist healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801833850.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seth Charatz, D.O has received a total of $412,665 in payments from pharmaceutical and medical device companies, with $8,105 received in 2024. These payments were reported across 675 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($351,142).
As a Medicare-enrolled provider, Charatz has provided services to 1,754 Medicare beneficiaries, totaling 2,263 services with total Medicare billing of $147,006. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Diabetes & Metabolism
- Location Rochester, NY
- Active Since 05/31/2006
- Last Updated 08/31/2022
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1801833850
Products in Payments
- FARXIGA (Drug) $61,833
- INVOKANA (Drug) $56,873
- Ozempic (Drug) $45,797
- JARDIANCE (Drug) $37,054
- Rybelsus (Drug) $34,338
- SOLIQUA 100/33 (Biological) $24,333
- BASAGLAR (Drug) $21,754
- Tresiba (Drug) $20,998
- RYBELSUS (Drug) $19,726
- SOLIQUA 100/33 (Drug) $17,756
- TOUJEO (Biological) $13,888
- TOUJEO (Drug) $11,305
- SOLIQUA (Drug) $8,738
- FIASP (Drug) $5,214
- Victoza (Drug) $3,101
- Saxenda (Drug) $2,040
- BYDUREON (Drug) $1,982
- AFREZZA (Drug) $650.00
- TRULICITY (Drug) $511.25
- Licart (Drug) $500.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospitalist Doctors in Rochester
Nelson Chan Hung, Md, MD
Hospitalist — Payments: $216,706
Hospitalist $216,706
Dr. Marcus Noel, Md, MD
Hospitalist — Payments: $44,034
Hospitalist $44,034
Waddah Malas, Md, MD
Hospitalist — Payments: $14,789
Hospitalist $14,789
Michael Hannon, M.d, M.D
Hospitalist — Payments: $4,555
Hospitalist $4,555
Julie Yoon, Md, MD
Hospitalist — Payments: $3,906
Hospitalist $3,906
Sunitha Bollineni, Md, MD
Hospitalist — Payments: $3,650
Hospitalist $3,650